Share Price and Basic Stock Data
Last Updated: October 8, 2025, 11:43 pm
| PEG Ratio | 2.50 |
|---|
Analyst Insight & Comprehensive Analysis
Beryl Drugs Ltd, a pharmaceutical company with a share price of ₹22.8 and a market capitalization of ₹11.5 Cr, exhibits a relatively high Price-to-Earnings (P/E) ratio of 50.2. This indicates that investors are willing to pay a premium for the company’s earnings compared to industry averages in India, which typically range between 20-30x. The Return on Equity (ROE) of 6.30% and Return on Capital Employed (ROCE) of 10.2% suggest moderate profitability levels for the company, falling within the lower range of sector benchmarks.
One key strength of Beryl Drugs is its stable operating profit margin (OPM) of 11.39%, which reflects efficient cost management. Additionally, the company’s Interest Coverage Ratio (ICR) of 10.28x indicates a comfortable ability to service its debt obligations. However, the company’s low ROE and ROCE levels compared to industry peers may pose risks in terms of suboptimal capital utilization and shareholder returns. Furthermore, the high P/E ratio could signal overvaluation, potentially leading to a price correction in the future. To improve its outlook, Beryl Drugs could focus on enhancing its operational efficiency and exploring avenues for revenue diversification.
In conclusion, while Beryl Drugs Ltd demonstrates stability in certain financial metrics, investors should carefully assess the company’s valuation and profitability against industry benchmarks. Conducting a thorough analysis of the company’s growth prospects and competitive positioning will be crucial in making informed investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Beryl Drugs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,792.62 Cr | 1,163.29 | 50.86 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.97 | 7.90 | 8.19 | 6.09 | 8.18 | 8.09 | 7.66 | 3.21 | 6.29 | 5.64 | 5.40 | 5.22 | 4.83 |
| Expenses | 4.37 | 7.27 | 7.47 | 5.82 | 7.05 | 7.37 | 6.87 | 3.19 | 5.30 | 5.08 | 4.81 | 4.72 | 4.28 |
| Operating Profit | 0.60 | 0.63 | 0.72 | 0.27 | 1.13 | 0.72 | 0.79 | 0.02 | 0.99 | 0.56 | 0.59 | 0.50 | 0.55 |
| OPM % | 12.07% | 7.97% | 8.79% | 4.43% | 13.81% | 8.90% | 10.31% | 0.62% | 15.74% | 9.93% | 10.93% | 9.58% | 11.39% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.13 | 0.11 | 0.12 | 0.06 | 0.12 | 0.10 | 0.11 | 0.13 | 0.21 | 0.12 | 0.12 | 0.08 | 0.10 |
| Depreciation | 0.25 | 0.19 | 0.22 | 0.15 | 0.28 | 0.29 | 0.31 | 0.32 | 0.28 | 0.33 | 0.31 | 0.32 | 0.38 |
| Profit before tax | 0.22 | 0.33 | 0.38 | 0.06 | 0.73 | 0.33 | 0.37 | -0.43 | 0.50 | 0.11 | 0.16 | 0.10 | 0.07 |
| Tax % | 0.00% | -6.06% | 60.53% | -16.67% | 27.40% | 18.18% | 16.22% | -16.28% | 26.00% | 90.91% | 62.50% | -50.00% | 71.43% |
| Net Profit | 0.22 | 0.34 | 0.14 | 0.06 | 0.53 | 0.27 | 0.31 | -0.35 | 0.37 | 0.01 | 0.05 | 0.15 | 0.02 |
| EPS in Rs | 0.43 | 0.67 | 0.28 | 0.12 | 1.05 | 0.53 | 0.61 | -0.69 | 0.73 | 0.02 | 0.10 | 0.30 | 0.04 |
Last Updated: August 19, 2025, 10:25 pm
Below is a detailed analysis of the quarterly data for Beryl Drugs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 4.83 Cr.. The value appears to be declining and may need further review. It has decreased from 5.22 Cr. (Mar 2025) to 4.83 Cr., marking a decrease of 0.39 Cr..
- For Expenses, as of Jun 2025, the value is 4.28 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.72 Cr. (Mar 2025) to 4.28 Cr., marking a decrease of 0.44 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.55 Cr.. The value appears strong and on an upward trend. It has increased from 0.50 Cr. (Mar 2025) to 0.55 Cr., marking an increase of 0.05 Cr..
- For OPM %, as of Jun 2025, the value is 11.39%. The value appears strong and on an upward trend. It has increased from 9.58% (Mar 2025) to 11.39%, marking an increase of 1.81%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.08 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.02 Cr..
- For Depreciation, as of Jun 2025, the value is 0.38 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.32 Cr. (Mar 2025) to 0.38 Cr., marking an increase of 0.06 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.03 Cr..
- For Tax %, as of Jun 2025, the value is 71.43%. The value appears to be increasing, which may not be favorable. It has increased from -50.00% (Mar 2025) to 71.43%, marking an increase of 121.43%.
- For Net Profit, as of Jun 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Mar 2025) to 0.02 Cr., marking a decrease of 0.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.04. The value appears to be declining and may need further review. It has decreased from 0.30 (Mar 2025) to 0.04, marking a decrease of 0.26.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:35 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14.54 | 13.23 | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.72 | 22.56 |
| Expenses | 13.77 | 12.50 | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.36 | 19.92 |
| Operating Profit | 0.77 | 0.73 | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.36 | 2.64 |
| OPM % | 5.30% | 5.52% | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.83% | 11.70% |
| Other Income | 0.18 | 0.18 | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 0.00 |
| Interest | 0.20 | 0.26 | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.55 | 0.53 |
| Depreciation | 0.32 | 0.52 | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.25 |
| Profit before tax | 0.43 | 0.13 | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.86 |
| Tax % | 37.21% | 38.46% | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 33.72% |
| Net Profit | 0.27 | 0.08 | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 |
| EPS in Rs | 0.53 | 0.16 | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -70.37% | 112.50% | -364.71% | 320.00% | -40.40% | -91.53% | 380.00% | -375.00% | 216.67% | 0.00% | -24.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 182.87% | -477.21% | 684.71% | -360.40% | -51.12% | 471.53% | -755.00% | 591.67% | -216.67% | -24.68% |
Beryl Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 16% |
| TTM: | -16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 63% |
| 3 Years: | 42% |
| TTM: | -62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | 29% |
| 3 Years: | 35% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 2:41 pm
Balance Sheet
Last Updated: September 10, 2025, 3:11 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.33 | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.41 |
| Borrowings | 1.53 | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.07 |
| Other Liabilities | 1.79 | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.39 |
| Total Liabilities | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
| Fixed Assets | 2.79 | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.20 |
| CWIP | 0.13 | 0.24 | 0.00 | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.73 | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 |
| Other Assets | 6.09 | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.76 |
| Total Assets | 9.74 | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.96 |
Below is a detailed analysis of the balance sheet data for Beryl Drugs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.09 Cr..
- For Reserves, as of Mar 2025, the value is 4.41 Cr.. The value appears strong and on an upward trend. It has increased from 3.83 Cr. (Mar 2024) to 4.41 Cr., marking an increase of 0.58 Cr..
- For Borrowings, as of Mar 2025, the value is 4.07 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.09 Cr. (Mar 2024) to 4.07 Cr., marking a decrease of 1.02 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2.39 Cr.. The value appears to be improving (decreasing). It has decreased from 3.48 Cr. (Mar 2024) to 2.39 Cr., marking a decrease of 1.09 Cr..
- For Total Liabilities, as of Mar 2025, the value is 15.96 Cr.. The value appears to be improving (decreasing). It has decreased from 17.49 Cr. (Mar 2024) to 15.96 Cr., marking a decrease of 1.53 Cr..
- For Fixed Assets, as of Mar 2025, the value is 6.20 Cr.. The value appears strong and on an upward trend. It has increased from 6.17 Cr. (Mar 2024) to 6.20 Cr., marking an increase of 0.03 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 9.76 Cr.. The value appears to be declining and may need further review. It has decreased from 11.32 Cr. (Mar 2024) to 9.76 Cr., marking a decrease of 1.56 Cr..
- For Total Assets, as of Mar 2025, the value is 15.96 Cr.. The value appears to be declining and may need further review. It has decreased from 17.49 Cr. (Mar 2024) to 15.96 Cr., marking a decrease of 1.53 Cr..
Notably, the Reserves (4.41 Cr.) exceed the Borrowings (4.07 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.76 | -0.99 | -1.19 | -1.78 | -0.44 | -2.22 | -4.32 | -3.67 | -4.85 | -2.54 | -2.73 | -1.43 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64.26 | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 |
| Inventory Days | 52.84 | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | |||
| Days Payable | 50.59 | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | |||
| Cash Conversion Cycle | 66.51 | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 |
| Working Capital Days | 36.90 | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 63.52 | 46.51 | 57.90 | 68.00 |
| ROCE % | 8.42% | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 | Mar 17 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.96 | 0.00 |
| Diluted EPS (Rs.) | 1.96 | 0.00 |
| PBDIT Margin (%) | 10.56 | 1.89 |
| PBIT Margin (%) | 8.50 | -1.38 |
| PBT Margin (%) | 7.67 | -3.12 |
| Net Profit Margin (%) | 6.21 | -3.59 |
| NP After MI And SOA Margin (%) | 6.21 | -3.59 |
| Interest Coverage Ratio (X) | 10.28 | -0.79 |
| Interest Coverage Ratio (Post Tax) (X) | 8.50 | -1.06 |
After reviewing the key financial ratios for Beryl Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 17) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For Diluted EPS (Rs.), as of Mar 18, the value is 1.96. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 17) to 1.96, marking an increase of 1.96.
- For PBDIT Margin (%), as of Mar 18, the value is 10.56. This value is within the healthy range. It has increased from 1.89 (Mar 17) to 10.56, marking an increase of 8.67.
- For PBIT Margin (%), as of Mar 18, the value is 8.50. This value is below the healthy minimum of 10. It has increased from -1.38 (Mar 17) to 8.50, marking an increase of 9.88.
- For PBT Margin (%), as of Mar 18, the value is 7.67. This value is below the healthy minimum of 10. It has increased from -3.12 (Mar 17) to 7.67, marking an increase of 10.79.
- For Net Profit Margin (%), as of Mar 18, the value is 6.21. This value is within the healthy range. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is 6.21. This value is below the healthy minimum of 8. It has increased from -3.59 (Mar 17) to 6.21, marking an increase of 9.80.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 10.28. This value is within the healthy range. It has increased from -0.79 (Mar 17) to 10.28, marking an increase of 11.07.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is 8.50. This value is within the healthy range. It has increased from -1.06 (Mar 17) to 8.50, marking an increase of 9.56.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Beryl Drugs Ltd:
- Net Profit Margin: 6.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.5
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 48.5 (Industry average Stock P/E: 50.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 133, Kanchan Bagh, Indore Madhya Pradesh 452001 | beryldrugs25@yahoo.com http://www.beryldrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Sethi | Chairman & Director |
| Mr. Sanjay Sethi | Managing Director |
| Mr. Abhinav Naik | Independent Director |
| Mrs. Shreya Saraf | Independent Woman Director |
FAQ
What is the intrinsic value of Beryl Drugs Ltd?
Beryl Drugs Ltd's intrinsic value (as of 10 October 2025) is 46.62 which is 111.91% higher the current market price of 22.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹11.2 Cr. market cap, FY2025-2026 high/low of 44.0/17.4, reserves of ₹4.41 Cr, and liabilities of 15.96 Cr.
What is the Market Cap of Beryl Drugs Ltd?
The Market Cap of Beryl Drugs Ltd is 11.2 Cr..
What is the current Stock Price of Beryl Drugs Ltd as on 10 October 2025?
The current stock price of Beryl Drugs Ltd as on 10 October 2025 is 22.0.
What is the High / Low of Beryl Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Beryl Drugs Ltd stocks is 44.0/17.4.
What is the Stock P/E of Beryl Drugs Ltd?
The Stock P/E of Beryl Drugs Ltd is 48.5.
What is the Book Value of Beryl Drugs Ltd?
The Book Value of Beryl Drugs Ltd is 18.7.
What is the Dividend Yield of Beryl Drugs Ltd?
The Dividend Yield of Beryl Drugs Ltd is 0.00 %.
What is the ROCE of Beryl Drugs Ltd?
The ROCE of Beryl Drugs Ltd is 10.2 %.
What is the ROE of Beryl Drugs Ltd?
The ROE of Beryl Drugs Ltd is 6.30 %.
What is the Face Value of Beryl Drugs Ltd?
The Face Value of Beryl Drugs Ltd is 10.0.